Skip to content

Released Mar 13, 2024, after the close

10-K filed Mar 13, 2024, 73 days after period end · 0000950170-24-030767

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$223.00Kderived−19.8% vs Q4 2022+2.3% vs Q3 2023
Net Income$51.21Mderived+91.2% vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$50,532,000+94.9%
Operating Cash Flowderived-$17,493,000N/M
Margins · derived
Operating margin22660.1%
Net margin22962.3%

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$223.00K$278.00K—$0.00
Net Income$51.21M$26.79M-$29.30M-$18.60M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR